Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital....

Descripción completa

Detalles Bibliográficos
Autores principales: Seppälä, Elina, Veneti, Lamprini, Starrfelt, Jostein, Danielsen, Anders Skyrud, Bragstad, Karoline, Hungnes, Olav, Taxt, Arne Michael, Watle, Sara Viksmoen, Meijerink, Hinta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414959/
https://www.ncbi.nlm.nih.gov/pubmed/34477054
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.35.2100793
_version_ 1783747880380530688
author Seppälä, Elina
Veneti, Lamprini
Starrfelt, Jostein
Danielsen, Anders Skyrud
Bragstad, Karoline
Hungnes, Olav
Taxt, Arne Michael
Watle, Sara Viksmoen
Meijerink, Hinta
author_facet Seppälä, Elina
Veneti, Lamprini
Starrfelt, Jostein
Danielsen, Anders Skyrud
Bragstad, Karoline
Hungnes, Olav
Taxt, Arne Michael
Watle, Sara Viksmoen
Meijerink, Hinta
author_sort Seppälä, Elina
collection PubMed
description Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0−27.4) and 64.6% (95% CI: 60.6−68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4−58.3) and 84.4% (95%CI: 81.8−86.5) against the Alpha variant.
format Online
Article
Text
id pubmed-8414959
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-84149592021-09-14 Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021 Seppälä, Elina Veneti, Lamprini Starrfelt, Jostein Danielsen, Anders Skyrud Bragstad, Karoline Hungnes, Olav Taxt, Arne Michael Watle, Sara Viksmoen Meijerink, Hinta Euro Surveill Rapid Communication Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0−27.4) and 64.6% (95% CI: 60.6−68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4−58.3) and 84.4% (95%CI: 81.8−86.5) against the Alpha variant. European Centre for Disease Prevention and Control (ECDC) 2021-09-02 /pmc/articles/PMC8414959/ /pubmed/34477054 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.35.2100793 Text en This article is copyright of the authors or their affiliated institutions, 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Seppälä, Elina
Veneti, Lamprini
Starrfelt, Jostein
Danielsen, Anders Skyrud
Bragstad, Karoline
Hungnes, Olav
Taxt, Arne Michael
Watle, Sara Viksmoen
Meijerink, Hinta
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
title Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
title_full Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
title_fullStr Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
title_full_unstemmed Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
title_short Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
title_sort vaccine effectiveness against infection with the delta (b.1.617.2) variant, norway, april to august 2021
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414959/
https://www.ncbi.nlm.nih.gov/pubmed/34477054
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.35.2100793
work_keys_str_mv AT seppalaelina vaccineeffectivenessagainstinfectionwiththedeltab16172variantnorwayapriltoaugust2021
AT venetilamprini vaccineeffectivenessagainstinfectionwiththedeltab16172variantnorwayapriltoaugust2021
AT starrfeltjostein vaccineeffectivenessagainstinfectionwiththedeltab16172variantnorwayapriltoaugust2021
AT danielsenandersskyrud vaccineeffectivenessagainstinfectionwiththedeltab16172variantnorwayapriltoaugust2021
AT bragstadkaroline vaccineeffectivenessagainstinfectionwiththedeltab16172variantnorwayapriltoaugust2021
AT hungnesolav vaccineeffectivenessagainstinfectionwiththedeltab16172variantnorwayapriltoaugust2021
AT taxtarnemichael vaccineeffectivenessagainstinfectionwiththedeltab16172variantnorwayapriltoaugust2021
AT watlesaraviksmoen vaccineeffectivenessagainstinfectionwiththedeltab16172variantnorwayapriltoaugust2021
AT meijerinkhinta vaccineeffectivenessagainstinfectionwiththedeltab16172variantnorwayapriltoaugust2021

Ejemplares similares